Cantor Fitzgerald initiated coverage of InflaRx (IFRX) with an Overweight rating and $10 price target
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx Approves Key Resolutions at Annual Shareholder Meeting
- InflaRx N.V. Announces 2025 Annual General Meeting Agenda
- InflaRx’s Promising Drug Pipeline and Market Potential Drive Buy Rating
- InflaRx price target raised to $10 from $7 at Guggenheim
- Promising Prospects for InflaRx’s Gohibic: Buy Rating Supported by Positive Phase 3 Developments and Market Potential